DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
Key Highlights
- ➤Q3 revenue $2.669 million, down from $3.013 million year over year
- ➤Q3 net income $10.536 million, versus a $34.318 million net loss
- ➤Diluted Q3 earnings $2.72 per share, versus a $23.07 loss
- ➤Corexa Pharmacy revenue rose 50% sequentially from Q2 2026
- ➤Nasdaq compliance restored October 19, 2026, including net equity requirement
Expert Statements
Gerald Commissiong, Interim Co-CEO of DataMEDS
“Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions.”
Gerald Commissiong, Interim Co-CEO of DataMEDS
“Health Lives Here, backed by NFL Alumni Health, brings patients to Corexa Pharmacy. The REBOOT license gives us patented, AI-assisted tools to keep GLP-1 patients engaged, proprietary Tollo Health medical foods for muscle loss associated with weight loss therapies gives them unique tools to mitigate the drugs' side effects and Helomics adds diagnostic testing revenue streams. With our first HMO relationship and compounded peptides opening new channels, and full Nasdaq compliance restored, we believe DataMEDS is well positioned for continued growth going forward.”
TAMPA, FL / ACCESS Newswire / November 13, 2026 / DataMEDS AI, Inc. ("DataMEDS AI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.
"Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions," said Gerald Commissiong, Interim Co-CEO of DataMEDS. "Health Lives Here, backed by NFL Alumni Health, brings patients to Corexa Pharmacy. The REBOOT license gives us patented, AI-assisted tools to keep GLP-1 patients engaged, proprietary Tollo Health medical foods for muscle loss associated with weight loss therapies gives them unique tools to mitigate the drugs' side effects and Helomics adds diagnostic testing revenue streams. With our first HMO relationship and compounded peptides opening new channels, and full Nasdaq compliance restored, we believe DataMEDS is well positioned for continued growth going forward."
Get started
Create a free account to read the full story.